Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Free Radic Biol Med. Author manuscript; available in PMC 2014 February 1.
Published in final edited form as:
PMCID: PMC3765090

Temporal patterns of tyrosine nitration in embryo heart development


Tyrosine nitration is a biomarker for the production of peroxynitrite and other reactive nitrogen species. Nitrotyrosine immunoreactivity is present in many pathological conditions including several cardiac diseases. Because the events observed during heart failure may recapitulate some aspects of development, we tested whether nitrotyrosine is present during normal development of the rat embryo heart and its potential relationship in cardiac remodeling through apoptosis. Nitric oxide (NO) production is highly dynamic during development, but whether peroxynitrite and nitrotyrosine are formed during normal embryonic development has received little attention. Rat embryo hearts exhibited strong nitrotyrosine immunoreactivity in endocardial and myocardial cells of the atria and ventricles from E12 to E18. After E18, nitrotyrosine staining faded and disappeared entirely by birth. Tyrosine nitration in the myocardial tissue coincided with elevated protein expression of nitric oxide synthases (eNOS and iNOS). The immunoreactivity for these NOS isoforms remained elevated even after nitrotyrosine had disappeared. Tyrosine nitration did not correlate with cell death or proliferation of cardiac cells. Analysis of tryptic peptides by MALDI-TOF shows that nitration occurs in actin, myosin, and the mitochondrial ATP synthase alpha chain. These results suggest that reactive nitrogen species are not restricted to pathological conditions but may play a role during normal embryonic development.


Nitric oxide was first described as the endothelial-derived relaxing factor, which modulates blood vessel relaxation by activating soluble guanylate cyclase [1]. Nitric oxide also modulates many other physiological processes, including neurotransmission, immune response, bone remodeling and muscle regeneration. Nitric oxide is produced through the oxidation of L-arginine to L-citrulline by three isoforms of the enzyme nitric oxide synthase (NOS), frequently identified as neuronal (nNOS), endothelial (eNOS) and inducible (iNOS) isoforms [2]. In addition to activating the cGMP pathway, nitric oxide also reacts at diffusion-limited rates with superoxide to form peroxynitrite that thereby initiates radical-mediated oxidation of lipids, DNA and proteins [2,3].

Nitration of tyrosine is a major footprint left by peroxynitrite and by myeloperoxidase-mediated oxidation of nitrite. It has emerged as a hallmark of oxidative tissue injury during acute and chronic inflammatory diseases in adult animals as well as in neurodegeneration. Studies of cardiac ischemia/reperfusion have found nitrotyrosine staining in the ischemic tissue and in myocarditis [46], whereas tissue from control animals is generally devoid of nitrotyrosine immunoreactivity. In addition, elevated serum levels of protein-bound nitrotyrosine can be predictive of cardiovascular disease in humans [7]. An increase in cardiac protein nitration occurs during both experimental and clinical settings of decompensated cardiac failure and may correlate with disease severity [8]. Production of reactive oxygen and nitrogen species has also been linked to apoptotic cell death [9,10]. For example, tyrosine nitration by peroxynitrite can kill motor neurons and PC12 by activating apoptotic pathways [1113], but does not necessarily induce cell death under all conditions [14,15]. Peroxynitrite has also been shown to mediate protective responses to endothelial shear stress by activating JNK and other signal transduction pathways [16,17].

In the course of examining whether tyrosine nitration would be found during the normal pruning of motor neurons in the spinal cord during embryogenesis, we were surprised to find tyrosine nitration present in the developing heart and other organs. It was well established that all three NOS isoforms are differentially expressed during normal heart embryonic development [18], consistent with nitric oxide having multifaceted roles in hearth development. However, a role for nitric oxide producing reactive nitrogen intermediates is unexpected during early development. Tyrosine nitration is known to occur during the regenerative processes induced by heart injury, which have been suggested to recapitulate embryogenesis [19,20]. Because nitrotyrosine is present during heart disease, we investigated whether tyrosine nitration was associated with the regions of remodeling involving cell death occurs during heart development [21] or was associated with other developmental events.


Pregnant female Sprague-Dawley rats of different gestational ages (6 rats per group, gestational ages from E10 to E21) were sacrificed with 100 mg/kg i.p. sodium pentobarbital (Abbott Laboratories, Chicago, IL) and the embryos obtained. We also used six newborn animals in each group from post-natal day 1 to 5. The embryos and newborn pups were then prepared for use in each of the techniques detailed below. The investigation conforms to the policies set forth in the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996).

Tissue preparation

For light microscopy studies, whole embryos harvested from day 10 to the end of the gestational period, were rapidly transferred to freshly prepared 4% paraformaldehyde, fixed overnight at 4°C, dehydrated and embedded in paraffin. Serial sections of 5 μm in thickness were cut parallel to the longitudinal axis of the heart including the trabeculated and compact parts of the wall of both ventricles and ventricular cavities. The sections were mounted on glass slides and stored at 4°C until further use.


Nitrotyrosine, iNOS and eNOS

Tissue sections from the hearts of embryos from different ages (E12-E19) and of newborns were immunostained as previously described [22]. Briefly, paraffin sections of the specimens were immunostained with a polyclonal anti-3-nitrotyrosine antibody [22,23], eNOS and iNOS antibodies (BD Biosciences, Franklin Lakes, NJ). Tissue sections were preincubated with 0.3% hydrogen peroxide in absolute methanol, washed in PBS, blocked with 10% goat serum, and incubated with the primary antibody. Immunoreactivity was visualized with DAKO Envision Kit (DAKO Corporation, Carpinteria, CA) according to the manufacturer’s instructions and then developed with diaminobenzidine (DAB). The slides were counterstained with hematoxylin. The specificity of the antibodies was examined by pre-absorbing the antibody with excess target protein or reducing agent dithionite for nitrotyrosine and by omitting the primary antibody for iNOS and eNOS.

Bromodeoxyuridine (BrdU)

For each pregnant rat of different gestational ages, 100 mg of BrdU (Sigma-Aldrich Corporation, St. Louis, MO) was dissolved in 8ml of saline and a total of four doses of 2 ml each were injected in 3-h intervals over a 12-hour period. The animals were sacrificed twenty-four hours after the last injection, the embryos were obtained, fixed by immersion in 4% paraformaldehyde (the duration of the fixation process depended on the size of the embryos), embedded in paraffin and sectioned. Slides were incubated overnight at 4°C with an antibody anti-BrdU (Dako Corporation, Carpinteria, CA), and the immunohistochemistry performed using a Dako Envision Doublestain System according to the manufacturer’s instructions. The colorimetric reaction was done using DAB/Fast Red.

Immunoprecipitation and Western Blotting


Ten to twelve hearts of the same age embryos (E10 to E21) as well as from postnatal (PN1-5) and adult rats were homogenized generating separated samples from each age group. They were sonicated in lysis buffer pH 7.4 (20mM Tris Base, 150mM NaCl, 10% glycerol, 1% Triton X-100, 4mM EDTA) containing protease inhibitors (Sigma Protease Inhibitor Cocktail, Sigma-Aldrich Corporation, St. Louis, MO) plus 1mM PMSF and 1mM orthovanadate. Lysates were microcentrifuged and supernatants were precleared using Gamma-Bind Plus Sepharose beads (Transduction-GE Healthcare Bio-Sciences Corp. Piscataway, NJ) for 1 hour at 4°C. Samples were incubated overnight with AminoLink Coupling Gel (Amersham-GE Healthcare Bio-Sciences Corp. Piscataway, NJ) and then labeled with anti-nitrotyrosine monoclonal antibody (UBI-Millipore, Billerica, MA). Proteins were electrophoresed, blotted and probed overnight with anti-nitrotyrosine polyclonal antibody and then for one additional hour with goat anti-rabbit HRP-conjugated secondary antibody (BioRad Laboratories, Hercules, CA). Blotted proteins were visualized using enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL). The samples did not were in contact with hydrogen peroxide until the development using enhanced chemiolumiscence, long after incubation with the antibodies.

Nitrated HSP90

Ten E15 heart embryos, ten two day-old post-natal hearts (PN-2) and three adult hearts were homogenized generating separated samples from each age group. They were sonicated in lysis buffer pH 7.4 (20mM Tris Base, 150mM NaCl, 10% glycerol, 1% Triton X-100, 4mM EDTA) containing protease inhibitors (Sigma Protease Inhibitor Cocktail, Sigma-Aldrich Corporation, St. Louis, MO) plus 1mM PMSF and 1mM orthovanadate. Lysates were centrifuged and supernatants were precleared using Gamma-Bind Plus Sepharose beads (Transduction-GE Healthcare Bio-Sciences Corp. Piscataway, NJ) for 1 hour at 4°C. Samples were incubated overnight with AminoLink Coupling Gel (Amersham-GE Healthcare Bio-Sciences Corp. Piscataway, NJ) and then labeled with anti-HSP90 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Proteins were electrophoresed, blotted and probed overnight with anti-nitrotyrosine monoclonal antibody and then for one additional hour with goat anti-rabbit HRP-conjugated secondary antibody (BioRad Laboratories, Hercules, CA). Blotted proteins were visualized using enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL).

Myeloperoxidase, Xanthine-Oxidase and NADPH-oxidase

Samples were prepared as described above for western blotting. Proteins were separated into three different SDS-polyacrylamide gels: of 8% for XO, 10% for NADPH-oxidase, and 15% for MPO. Then they were electrophoresed, blotted and probed overnight with the corresponding primary antibody: anti-XO polyclonal antibody (Rockland Immunochemicals, Gilbertsville, PA), anti-NADPH-oxidase gp91 phox subunit polyclonal antibody (gift from Dr. M. Quinn, Montana State University), anti-MPO polyclonal antibody (Biomeda, Foster City, CA) and then incubated for one additional hour with goat anti-rabbit HRP-conjugated secondary antibody (BioRad). Blotted proteins were visualized using enhanced chemiluminescence (Pierce).

iNOS in situ Hybridization

A 405bp of rat iNOS cDNA was amplified with the following primers 5′-CTGGAATTCCCAGCTCATCC-3′ y 5′-TCCTCCAGGATGTTGTAGCG-3′ and cloned into a pGEM-T vector (Promega, Madison, WI). Following sequencing and linearization, sense and anti-sense biotin labeled–riboprobes were synthesized with SP6/T7 RNA polymerases, using a DIG RNA labeling kit (Roche, Indianapolis, IN) according to manufacturer instructions.

Paraffin was removed from tissue sections from E15 rat embryos before they were pretreated with 20μg proteinase K (Sigma-Aldrich) for 30 minutes at 37°C. In order to inhibit endogenous peroxidase activity specimens were treated with 3% hydrogen peroxide in absolute methanol for 10 minutes at −20°C. The slides were incubated in a hybridization buffer for 30 minutes at 55°C and hybridized overnight with 20ng/ml iNOS biotinylated probe at the same temperature. The probe was detected using the Tyramide Signal Amplification-Cy3 Fluorescence System (NEN-Perkin Elmer, Boston, MA), counterstained with DAPI and mounted with Slow-Fade (Molecular Probes-Invitrogen, Eugene, OR).


Serial sections of rat embryos of varying ages were labeled with DeadEnd Colorimetric Apoptosis Detection System (Promega, Madison, WI), a modified TUNEL assay, according to the manufacturer’s instructions. Briefly, sections were fixed with 4% paraformadehyde in 0.1M PBS, permeabilized with 20μg proteinase K for 25 minutes, incubated with a mixture of biotinylated nucleotides and TdT enzyme for one hour at 37°C. HRP-labeled streptavidin were then bound to these nucleotides that had been detected using hydrogen peroxide and DAB. Apoptotic nuclei stained dark brown.

Mass Spectrometry

Tissue homogenates were immunoprecipitated with antibody anti-nitrotyrosine as described above and separated by SDS-page. The protein was identified by analysis of tryptic fragments and comparing them with those of the NCBI database. The procedure used was adapted from that developed at UCSF ( Briefly, the bands were excised from a polyacrylamide gel, digested overnight with trypsin, and the peptides were extracted with 50% acetonitrile/5% formic acid. The extracts were concentrated and re-dissolved in 10μl 50% acetonitrile/5% formic acid. The extracted peptides were mixed with the matrix α-cyano-4-hydroxycinnamic acid (CHCA) (Sigma-Aldrich, St Louis, MI), spotted onto a MALDI plate and analyzed with a Voyager DePro mass spectrometer (Applied Biosystems, Foster City, CA). The peptide masses were searched via Mascot ( and the NCBI database to identify immunoprecipitated proteins.

Actin peptide sequencing and detection of nitrotyrosine was performed using a mass spectrometer Waters-Micromass Qtof II. Doubly- or triply-charged parent ions were detected in the first quadrupole and if above a predefined threshold, the ion is selected, carried into a collision cell where fragmentation occurs, and the ions are detected by an orthogonal TOF detector to produce the tandem mass spectrum. Manual de novo sequencing was the principal method used to interpret the spectra. The MSMS spectra were processed to remove noise and then processed via MaxEnt3 software. This processing allows for rapid identification of ions in y-ion and b-ion series. The peak lists from each MS-MS spectrum were analyzed by PROWL (Rockefeller University) to determine their peptide sequence.


Nitrotyrosine in Normal Embryonic Heart Development

Rat embryonic hearts showed a striking and specific anatomical and temporal distribution of tyrosine nitration. Immunoreactivity for nitrotyrosine was localized in the cytoplasm of endocardial and myocardial cells mainly in the ventricle wall from E11 to E18 (Fig. 1). At E11, the compact wall of the ventricles is thin and the first short trabeculae carneae forms in the spongy zone. At this stage, nitrotyrosine immunoreactivity was found almost exclusively in endocardial cells lining the trabeculae of the ventricular wall. The ventricular trabeculae were the primary sites of nitration during the mid gestation period. As the myocardium develops during E12-14, the thickness of the compact wall and the number of trabeculae increases. During this time, nitrotyrosine staining declined in the endothelial cells and became more predominant in the myocytes of the ventricular trabeculae (Fig. 2). Around E15 the compact myocardium also showed nitrotyrosine immunoreactivity, which remained evident until E18. The immunoreactivity for nitrotyrosine decreased markedly at the end of the gestational period. Starting at E18, only weak staining in the myocardium was observed and no nitrotyrosine immunoreactivity could be found in the heart in the last few days of gestation or after birth. Nitration was also observed in other organ systems, such as the developing vertebra.

Fig 1
Nitrotyrosine Immunoreactivity in Rat Embryonic Cardiac Development
Fig. 2
Nitrotyrosine, eNOS and iNOS immunoreactivity in E12 Rat Embryo Heart Development

Mass Spectroscopy Analysis of Nitrated Cardiac Muscle Proteins

To identify what proteins were nitrated, E15 heart homogenates were immunoprecipitated with nitrotyrosine antibodies and resolved by SDS-PAGE. The MALDI-TOF analysis of tryptic peptides revealed that the cytoskeletal proteins α-actin and β-myosin heavy chain were the main targets for protein nitration as well as the α-chain of Ca2+ATP synthase (Table I). These three protein targets have been previously reported as nitrated in heart disease and aging [2,24]. Further analysis of α-actin trypsin fragments by MALDI-TOF-TOF showed that the tyrosine residues 55 and 200 were nitrated (Fig. 3). The nitration of these proteins was also confirmed by immunoprecipitation of the protein followed by Western blot using nitrotyrosine antibody. Western blot analysis of nitration of β-myosin heavy chain showed a temporal pattern identical to that revealed by immunohistochemistry (Fig. 4).

Fig. 3
Identification of Nitrated Tyrosine Residues in cardiac muscle
Fig. 4
Western Blot analysis of nitrated proteins in the embryo heart
Table I
Identification of nitrated proteins by MALDI-TOF analysis of tryptic peptides

Not all proteins were nitrated in the embryonic heart. Previously, we have shown that Hsp90 was nitrated in several pathological conditions including amyotrophic lateral sclerosis [12,25]. Nitrated Hsp90 was not detected in heart from E15 embryos, in two-day old post-natal pups or in control adults, but was nitrated in hypertrophic adult hearts. Thus, certain proteins such as Hsp90 may be preferentially nitrated in pathological conditions, but not necessarily during normal heart development (Fig. 5).

Fig. 5
Comparison between nitrotyrosine immunostaining versus apoptosis and DNA synthesis in rat embryonic cardiac development

Unexpectedly, an opposing pattern of localization was observed between apoptotic nuclei and nitrotyrosine immunoreactivity. Apoptotic nuclei were found mainly in the compact myocardium of the left and right ventricles and in the infundibular section of the right ventricle where cells proliferate. Nitrotyrosine was confined mainly to the trabeculae of both atria and ventricles, where most of the cells had fully differentiated (Fig. 6). Proliferating cells identified with bromouridine did not show nitrotyrosine immunoreactivity. In summary, nitrotyrosine immunoreactivity was principally located in terminally differentiated cells and was not associated with either proliferation or apoptosis.

Fig. 6
Hsp90 nitration in heart

iNOS and eNOS are Present During Cardiac Development

The developing heart was immunoreactive for the endothelial and inducible isoforms of NOS. Immunoreactivity for endothelial NOS was localized in endocardial and myocardial cells in the compact myocardium as well as the trabeculae (Fig. 2 and and7).7). Immunoreactivity for the inducible NOS was localized in the atrial and ventricular myocardium of the embryonic heart (Fig. 2 and and8).8). Both NOS isoforms were present throughout development, including the latest stages of heart formation and even after birth. The protein expression and distribution of iNOS was confirmed by in situ hybridization in E15 hearts. The iNOS mRNA and protein immunoreactivity were distributed identically (Fig. 9).

Fig. 7
Endothelial NOS immunohistochemistry in the rat cardiac development
Fig. 8
Inducible NOS immunohistochemistry in the rat cardiac development
Fig. 9
In situ hybridization for NOS II in rat embryonic hearts

Myeloperoxidase, Xanthine-Oxidase And NADPH Oxidase Protein Expression

To test whether the decrease in nitrotyrosine is due to changing levels of superoxide or hydrogen peroxide formation, the protein expression of XO, MPO and NADPH-oxidase was investigated during heart development (Fig. 10). Western blot analysis of protein extracts from embryo hearts showed that MPO become detectable starting at E16 up until birth and post-natal ages, whereas XO started protein expression at E19 and continued to increase its levels after birth. In contrast, the gp91 phox subunit of the NADPH-oxidase was not expressed until adulthood (Fig. 10).

Fig. 10
Western blots analysis for MPO, XO and NADPH-oxidase in rat embryonic hearts


The temporal and anatomical distribution patterns of nitrotyrosine during heart development reveal that the generation of reactive nitrogen species responsible for nitration is spatially restricted and highly dynamic. At certain stages of development, apoptosis occurs in well-defined segments of the heart to help shape its final structure. Surprisingly, nitrotyrosine levels did not correlate with apoptotic heart remodeling but was rather associated with myocyte differentiation. Supporting this conclusion, two proteins of the contractile cardiac sarcomere, β-myosin heavy chain and α-actin were nitrated in the embryonic heart. Nitration of these proteins may potentially modify contractile force during the embryonic period. A growing body of evidence indicates that tyrosine nitration of contractile proteins can reduce myocardial contractility. In isolated human myocardial cells, nitration of proteins such as α-actinin alters their contractile properties [26]. Exposure of rat ventricular trabeculae to physiologically relevant concentrations of peroxynitrite impairs the maximal trabecular force generation and leads to the nitration of several myofibrillar proteins including myosin heavy chain [8].

Myosin heavy chain (MHC), a major contractile protein that converts chemical energy from ATP into mechanical force, has two isoforms. The beta isoform is predominant during embryonic development and is replaced at birth by the alpha isoform [27]. The alpha isoform increases the maximum sarcomere shortening velocity in the adult heart. The embryonic beta isoform is characterized by lower ATPase activity and slower filament sliding velocity, but it can generate a cross-bridge force with a higher economy of energy consumption than the alpha isoform. In failing mouse and human adult hearts, severe cardiovascular stress triggers a shift from α- to β-MHC, essentially causing expression to revert to an embryonic pattern [28]. Our results show that the nitration occurred in the β-MHC but disappeared at birth as the expression of α-MHC increased, suggesting that β-MHC could be a selective target for nitration. The adaptive significance of β-MHC nitration could be the reduction in cardiac pump function, because the amount of nitration corresponds to the decrease in cardiac pump function in isolated hearts [29].

Interestingly, the pattern of embryonic gene expression shares features with cardiac hypertrophy [21]. The embryonic proteins, β-MHC and skeletal actin, are induced following aortic stenosis [30] and in cardiac hypertrophy [19]. The “reactivation” of the fetal gene expression is also supported by the similarities in myofibrillar formation in re-differentiating adult cardiomyocytes with their embryonic counterparts during development [3133].

The expression of two nitric oxide synthases isoforms (eNOS and iNOS) during development is consistent with previous reports [18,34,35]. NO production by eNOS alone has been implicated in promoting angiogenesis and vasculogenesis. It also mediates the activities of many angiogenic factors such as VEGF [36,37]. Inhibition of NO production significantly reduced the number of mature myocytes, directly implicating NO in cardiomyocyte differentiation. While nitrotyrosine and NOS isoforms colocalize at early embryonic ages, NOS isoforms remain detectable in post-natal stages long after nitrotyrosine immunoreactivity disappeared [34]. These results are consistent with nitric oxide itself not being responsible for nitration, but rather requiring the formation other reactive nitrogen species to nitrate tyrosine in proteins [2].

The gene deletion of each of the NOS isoforms leads to specific sets of functional and morphological abnormalities. Particularly relevant to the development of the embryonic cardiovascular system, eNOS knock-out mice exhibit hypertension, atherosclerosis, abnormal aortic valve development and heart failure and congenital septal defects [3841]. While the deletion of the eNOS gene does not block heart development, it causes developmental abnormalities that are still compatible with embryonic survival. This may be due to compensatory mechanisms utilizing the other NOS isoforms [42].

Tyrosine can be nitrated by a number of different mechanisms that involve reactions with superoxide and hydrogen peroxide [2]. The reaction of peroxynitrite with carbon dioxide to form carbonate radical and nitrogen dioxide is a major contributor to nitration in vivo [43,44]. Tyrosine nitration can also be catalyzed from hydrogen peroxide and nitrite by peroxidases such as MPO [45,46]. In the developing heart, nitrotyrosine immunoreactivity was present long before myeloperoxidase expression was detectable. Because NOS is expressed both during embryonic development and after birth, nitrotyrosine might be controlled by increased superoxide production. Xanthine oxidase and NADPH oxidase are major sources of superoxide in events associated with inflammation and ischemia/reperfusion. However, their expression increased as nitrotyrosine decreased, suggesting that alternative sources of superoxide or hydrogen peroxide exist in the embryonic heart.

Taken together, our results lead to the surprising conclusion that tyrosine nitration, most likely mediated by peroxynitrite, is a physiological phenomenon occurring during embryogenesis. The nitration of proteins observed in adult diseased hearts could be the recapitulation of events found normally in embryogenesis to modulate tissue repair processes. However, physiological nitration is not restricted to the embryo heart and was previously described in aging heart mitochondria and in the placenta. In both conditions, the levels of nitration were greatly increased in disease conditions [15,47]. Nitrotyrosine in the normal chorioallantoic membrane chick embryo suggest that tyrosine nitration may be a conserved evolutive trait [48]. Tyrosine nitration also was found in the normal development of the tunicate Ciona intestinalis supporting role for tyrosine nitration early in the evolution [49]. The long-term consequences of modifying tissue proteins by such a highly reactive oxidant are likely minimized by restriction of nitration to terminally differentiated tissues, which may serve to reinforce terminal differentiation.


  • Nitrotyrosine is formed during normal heart embryo development
  • Nitrotyrosine is present in differentiated cells
  • Nitrotyrosine is not detected after day E18 and remains absent in adult heart
  • Tyrosine nitration disappears even though eNOS and iNOS are expressed
  • Only nitrated Hsp90 was identified in heart pathology but not in development


The authors thank Dr. Gabriela Bedó (Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay) for helping with the making of the iNOS probe, Dolores Madden y Angela Cirillo for her support with the histological preparations and Marion Kirk for the technical help with the mass spectrometric analysis. Funds for the purchase of the mass spectrometers were from NIH/NCRR Shared Instrumentation Grant Awards RR06487 and RR13795. Operation of the Mass Spectrometry Shared Facility is supported by NCI Core Support Grant P30 CA13148. The investigations were supported by the Burke Medical Research Institute, NIH grants NS36761, NS42834 (AGE), and NS058628, AT002034 and ES00210 (JSB)


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Moncada S, Palmer RMJ, Higgins EA. Nitric oxide: physiology, pathophysiology, phamacology. Pharmacol Rev. 1991;43:109–142. [PubMed]
2. Pacher P, Beckman JS, Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiol Rev. 2007;87:315–424. [PMC free article] [PubMed]
3. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochemical and Biophysical Research Communications. 2003;305:776–783. [PubMed]
4. Kooy NW, Lewis SJ, Royall JA, Ye YZ, Kelly DR, Beckman JS. Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite. Crit Care Med. 1997;25:812–9. [PubMed]
5. Liu P, Hock CE, Nagele R, Wong PY. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. The American journal of physiology. 1997;272:H2327–36. [PubMed]
6. Szabo G, Loganathan S, Merkely B, Groves JT, Karck M, Szabo C, Radovits T. Catalytic peroxynitrite decomposition improves reperfusion injury after heart transplantation. J Thorac Cardiovasc Surg. 2012;143:1443–9. [PMC free article] [PubMed]
7. Shishehbor MH, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA: the journal of the American Medical Association. 2003;289:1675–80. [PubMed]
8. Mihm MJ, Yu F, Reiser PJ, Bauer JA. Effects of peroxynitrite on isolated cardiac trabeculae: selective impact on myofibrillar energetic controllers. Biochimie. 2003;85:587–96. [PubMed]
9. Tao L, Liu HR, Gao F, Qu Y, Christopher TA, Lopez BL, Ma XL. Mechanical traumatic injury without circulatory shock causes cardiomyocyte apoptosis: role of reactive nitrogen and reactive oxygen species. Am J Physiol Heart Circ Physiol. 2005;288:H2811–8. [PubMed]
10. Estevez AG, Radi R, Barbeito L, Shin JT, Thompson JA, Beckman JS. Peroxynitrite-induced cytotoxicity in PC12 cells: evidence for an apoptotic mechanism differentially modulated by neurotrophic factors. J Neurochem. 1995;65:1543–50. [PubMed]
11. Shacka JJ, Sahawneh MA, Gonzalez JD, Ye YZ, D’Alessandro TL, Estévez AG. Two distinct signaling pathways regulate peroxynitrite-induced apoptosis in PC12 cells. Cell Death Differ. 2006;13:1506–1514. [PubMed]
12. Ye Y, et al. Prevention of peroxynitrite-induced apoptosis of motor neurons and PC12 cells by tyrosine-containing peptides. J Biol Chem. 2007;282:6324–6337. [PubMed]
13. Franco MC, Estevez AG. Reactive Nitrogen Species in Motor Neuron Apoptosis. In: Maurer MH, editor. Amyotrophic Lateral Sclerosis. InTech; 2012.
14. Garcia-Nogales P, Almeida A, Bolanos JP. Peroxynitrite protects neurons against nitric oxide-mediated apoptosis. A key role for glucose-6-phosphate dehydrogenase activity in neuroprotection. The Journal of biological chemistry. 2003;278:864–74. [PubMed]
15. Webster RP, Roberts VH, Myatt L. Protein nitration in placenta - functional significance. Placenta. 2008;29:985–94. [PMC free article] [PubMed]
16. Go YM, Patel RP, Maland MC, Park H, Beckman JS, Darley-Usmar VM, Jo H. Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of c-Jun NH(2)-terminal kinase. The American journal of physiology. 1999;277:H1647–53. [PubMed]
17. Patel RP, Levonen A, Crawford JH, Darley-Usmar VM. Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovasc Res. 2000;47:465–74. [PubMed]
18. Bloch W, Fleischmann BK, Lorke DE, Andressen C, Hops B, Hescheler J, Addicks K. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res. 1999;43:675–84. [PubMed]
19. Morkin E. Control of cardiac myosin heavy chain gene expression. Microsc Res Tech. 2000;50:522–31. [PubMed]
20. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551–71. [PubMed]
21. Ghatpande S, Goswami S, Mascareno E, Siddiqui MA. Signal transduction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy. Mol Cell Biochem. 1999;196:93–7. [PubMed]
22. Viera L, Ye YZ, Beckman JS. Anti-nitrotyrosine antibodies for immunohistochemistry. In: Evans T, translator. Methods in Molecular Medicine: Septic Shock Methods and Protocols. Humana Press; Totowa, NY: 1999. pp. 159–169.
23. Ye YZ, Strong M, Huang Z-Q, Beckman JS. Antibodies that recognize nitrotyrosine. In: Packer L, editor. Methods in Enzymology. Academic Press; San Diego: 1996. pp. 201–209. [PubMed]
24. Kanski J, Behring A, Pelling J, Schoneich C. Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. Am J Physiol Heart Circ Physiol. 2005;288:H371–81. [PubMed]
25. Basso M, et al. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One. 2009;4:e8130. [PMC free article] [PubMed]
26. Borbely A, et al. Peroxynitrite-induced alpha-actinin nitration and contractile alterations in isolated human myocardial cells. Cardiovasc Res. 2005;67:225–33. [PubMed]
27. Siedner S, et al. Developmental changes in contractility and sarcomeric proteins from the early embryonic to the adult stage in the mouse heart. The Journal of physiology. 2003;548:493–505. [PubMed]
28. Krenz M, Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. Journal of the American College of Cardiology. 2004;44:2390–7. [PubMed]
29. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circulation research. 2000;87:241–7. [PubMed]
30. Schiaffino S, et al. Nonsynchronous accumulation of alpha-skeletal actin and beta-myosin heavy chain mRNAs during early stages of pressure-overload--induced cardiac hypertrophy demonstrated by in situ hybridization. Circulation research. 1989;64:937–48. [PubMed]
31. Nag AC, Lee ML. Breakdown and rebuilding of myofibrils in cultured adult cardiac muscle cells. Tsitologiia. 1997;39:907–12. [PubMed]
32. Sanger JW, Ayoob JC, Chowrashi P, Zurawski D, Sanger JM. Assembly of myofibrils in cardiac muscle cells. Advances in experimental medicine and biology. 2000;481:89–102. discussion 103–5. [PubMed]
33. Bird SD, Doevendans PA, van Rooijen MA, Brutel de la Riviere A, Hassink RJ, Passier R, Mummery CL. The human adult cardiomyocyte phenotype. Cardiovasc Res. 2003;58:423–34. [PubMed]
34. Ursell PC, Mayes M. Anatomic distribution of nitric oxide synthase in the heart. Int J Cardiol. 1995;50:217–23. [PubMed]
35. Ursell PC, Mayes M. Endothelial isoform of nitric oxide synthase in rat heart increases during development. Anat Rec. 1996;246:465–72. [PubMed]
36. Kashiwagi S, et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. The Journal of clinical investigation. 2005;115:1816–27. [PubMed]
37. Hou HH, et al. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc Res. 2012;93:120–9. [PMC free article] [PubMed]
38. Kubis N, Richer C, Domergue V, Giudicelli JF, Levy BI. Role of microvascular rarefaction in the increased arterial pressure in mice lacking for the endothelial nitric oxide synthase gene (eNOS3pt−/−) Journal of hypertension. 2002;20:1581–7. [PubMed]
39. Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation. 2000;101:2345–8. [PubMed]
40. Lee PC, et al. Endothelial nitric oxide synthase protects aortic allografts from the development of transplant arteriosclerosis. Transplantation. 2000;69:1186–92. [PubMed]
41. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, Yee SP. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation. 2002;106:873–9. [PubMed]
42. Huang CH, Vatner SF, Peppas AP, Yang G, Kudej RK. Cardiac nerves affect myocardial stunning through reactive oxygen and nitric oxide mechanisms. Circulation research. 2003;93:866–73. [PubMed]
43. Augusto O, Bonini MG, Amanso AM, Linares E, Santos CCX, De Menezes SL. Nitrogen dioxide and carbonate radical anion: two emerging radicals in biology. Free Radical Biology and Medicine. 2002;32:841–859. [PubMed]
44. Bonini MG, Radi R, Ferrer-Sueta G, Ferreira AMDC, Augusto O. Direct EPR Detection of the Carbonate Radical Anion Produced from Peroxynitrite and Carbon Dioxide. J Biol Chem. 1999;274:10802–10806. [PubMed]
45. van der Vliet A, Eiserich JP, Halliwell B, Cross CE. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem. 1997;272:7617–25. [PubMed]
46. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391:393–7. [PubMed]
47. Padrao AI, Ferreira R, Vitorino R, Alves RM, Figueiredo P, Duarte JA, Amado F. Effect of lifestyle on age-related mitochondrial protein oxidation in mice cardiac muscle. Eur J Appl Physiol. 2012;112:1467–74. [PubMed]
48. Giannopoulou E, Katsoris P, Polytarchou C, Papadimitriou E. Nitration of cytoskeletal proteins in the chicken embryo chorioallantoic membrane. Arch Biochem Biophys. 2002;400:188–98. [PubMed]
49. Ercolesi E, Tedeschi G, Fiore G, Negri A, Maffioli E, d’Ischia M, Palumbo A. Protein nitration as footprint of oxidative stress-related nitric oxide signaling pathways in developing Ciona intestinalis. Nitric Oxide. 2012;27:18–24. [PubMed]